Management of Type IIb Dyslipidemia

被引:11
作者
Arai, Hidenori [1 ]
Ishibashi, Shun
Bujo, Hideaki [2 ]
Hayashi, Toshio [3 ]
Yokoyama, Shinji [4 ]
Oikawa, Shinichi [5 ]
Kobayashi, Junji [6 ]
Shirai, Kohji [7 ]
Ota, Takao [8 ]
Yamashita, Shizuya [9 ]
Gotoda, Takanari [10 ]
Harada-Shiba, Mariko [11 ]
Sone, Hirohito [12 ]
Eto, Masaaki [13 ,14 ]
Suzuki, Hiroaki [15 ]
Yamada, Nobuhiro
机构
[1] Kyoto Univ, Grad Sch Med, Dept Human Hlth Sci, Kyoto, Japan
[2] Chiba Univ, Grad Sch Med, Dept Genome Res & Clin Applicat, Chiba, Japan
[3] Nagoya Univ, Dept Geriatr, Grad Sch Med, Nagoya, Aichi 4648601, Japan
[4] Nagoya City Univ, Grad Sch Med Sci, Dept Biochem, Nagoya, Aichi, Japan
[5] Nippon Med Sch, Div Endocrinol & Metab, Dept Med, Tokyo 113, Japan
[6] Kanazawa Univ, Dept Lipidol, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan
[7] Toho Univ, Sakura Hosp, Sch Med, Chiba 2748510, Japan
[8] Univ Ryukyus, Dept Child Hlth & Welf Pediat, Fac Med, Okinawa, Japan
[9] Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Osaka, Japan
[10] Tokyo Univ Hosp, Dept Clin & Mol Epidemiol, 22nd Century Med & Res Ctr, Tokyo 113, Japan
[11] Natl Cerebral & Cardiovasc Ctr, Dept Mol Innovat Lipidol, Res Inst, Osaka, Japan
[12] Univ Tsukuba, Inst Clin Med, Dept Internal Med, Ibaraki, Japan
[13] Ohu Univ, Sch Pharmaceut Sci, Fukushima, Japan
[14] Ohu Univ Hosp, Dept Med, Fukushima, Japan
[15] Univ Tsukuba, Dept Endocrinol & Metab, Grad Sch Comprehens Human Sci, Ibaraki, Japan
关键词
Atherogenic dyslipidemia; Cardiovascular disease; Diabetes; Metabolic syndrome; Lifestyle modification; CORONARY-HEART-DISEASE; FAMILIAL COMBINED HYPERLIPIDEMIA; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASES; GENERAL JAPANESE POPULATION; POLYUNSATURATED FATTY-ACIDS; PLACEBO-CONTROLLED TRIAL; SOCIETY JAS GUIDELINE; NON-HDL CHOLESTEROL; ARTERY-DISEASE; RISK-FACTORS;
D O I
10.5551/jat.10447
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Although the Japan Atherosclerosis Society guideline for the diagnosis and prevention of atherosclerosis cardiovascular diseases for the Japanese population provides targets for low-density lipoprotein (LDL) cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol to prevent cardiovascular disease in patients with dyslipidemia, there is no guideline specifically targeting the treatment of type IIb dyslipidemia, which is one of the most common types of dyslipidemia, along with type IIa and type IV dyslipidemia. Type IIb dyslipidemia is important because it sometimes accompanies atherogenic lipid profiles, such as small, dense LDL, remnants, low HDL cholesterolemia. It is also associated with type 2 diabetes mellitus, metabolic syndrome, and chronic kidney disease (CKD), and most patients with familial combined hyperlipidemia (FCHL) show this phenotype; therefore, it is assumed that patients with type IIb dyslipidemia have a high risk for cardiovascular disease. Thus, the management of type IIb dyslipidemia is very important for the prevention of cardiovascular disease, so we have attempted to provide a guideline for the management of type IIb dyslipidemia.
引用
收藏
页码:105 / 114
页数:10
相关论文
共 63 条
[1]  
[Anonymous], LANCET
[2]  
[Anonymous], 1975, JAMA, V231, P360
[3]  
[Anonymous], 2000, CIRCULATION, V102, P21
[4]  
Ansquer JC, 2009, AM J CARDIOVASC DRUG, V9, P91, DOI 10.2165/00129784-200909020-00003
[5]   Serum lipid survey and its recent trend in the general Japanese population in 2000 [J].
Arai, H ;
Yamamoto, A ;
Matsuzawa, Y ;
Saito, Y ;
Yamada, N ;
Oikawa, S ;
Mabuchi, H ;
Teramoto, T ;
Sasaki, J ;
Nakaya, N ;
Itakura, H ;
Ishikawa, Y ;
Ouchi, Y ;
Horibe, H ;
Kita, T .
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2005, 12 (02) :98-106
[6]   Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men [J].
Assmann, G ;
Schulte, H ;
vonEckardstein, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (14) :1179-1184
[7]   Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia [J].
Athyros, VG ;
Papageorgiou, AA ;
Athyrou, VV ;
Demitriadis, DS ;
Kontopoulos, AG .
DIABETES CARE, 2002, 25 (07) :1198-1202
[8]   Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia [J].
Athyros, VG ;
Papageorgiou, AA ;
Hatzikonstandinou, HA ;
Didangelos, TP ;
Carina, MV ;
Kranitsas, DF ;
Kontopoulos, AG .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (05) :608-613
[9]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[10]   Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S [J].
Ballantyne, CM ;
Olsson, AG ;
Cook, TJ ;
Mercuri, MF ;
Pedersen, TR ;
Kjekshus, J .
CIRCULATION, 2001, 104 (25) :3046-3051